The Study of Ocular Hemodynamics With Glaucoma Progression
IGPS
1 other identifier
observational
123
1 country
1
Brief Summary
To determine the relationships between ocular hemodynamics and glaucomatous optic neuropathy progression.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Jan 2008
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2008
CompletedFirst Submitted
Initial submission to the registry
June 15, 2010
CompletedFirst Posted
Study publicly available on registry
June 17, 2010
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 3, 2014
CompletedStudy Completion
Last participant's last visit for all outcomes
July 3, 2014
CompletedMarch 7, 2017
March 1, 2017
6.5 years
June 15, 2010
March 6, 2017
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Ocular Blood Flow
per visit
various
Study Arms (1)
Glaucoma patients
Glaucoma patients
Eligibility Criteria
Glaucoma patients
You may qualify if:
- Age: 30 years or older.
- Diagnosis: confirmed open-angle glaucoma in at least one eye:
- glaucomatous visual field loss on Humphrey 24-2 or 10-2 perimetry
- glaucomatous optic disc cupping
- agreement between two baseline exams for reliability
- Best corrected visual acuity at least 20/60 in at least one eye.
- Prior Humphrey visual fields demonstrate acceptable reliability standards (see below).
You may not qualify if:
- Extensive Humphrey visual field damage consisting of either a mean deviation (MD) \< -15 decibels or a clinically determined threat to fixation in both hemifields.
- Evidence of exfoliation or pigment dispersion.
- History of acute angle-closure or a narrow, occludable anterior chamber angle by gonioscopy.
- History of chronic or recurrent inflammatory eye diseases (e.g., scleritis, uveitis).
- History or signs of intraocular trauma.
- Severe or potentially progressive retinal disease such as retinal degeneration, diabetic retinopathy, and retinal detachment.
- Any abnormality preventing reliable applanation tonometry.
- Current use of any ophthalmic or systemic steroid which may interfere with this investigation.
- Cataract surgery within the past year.
- Resting pulse \< 50 beats per minute.
- Severe, unstable or uncontrolled cardiovascular, renal, or pulmonary disease.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Indiana University School of Medicine, Department of Ophthalmology
Indianapolis, Indiana, 46202, United States
Related Publications (1)
Verticchio Vercellin AC, Harris A, Oddone F, Siesky B, Eckert G, Belamkar A, Antman G, Segev F. Ocular blood flow biomarkers may predict long-term glaucoma progression. Br J Ophthalmol. 2024 Jun 20;108(7):946-950. doi: 10.1136/bjo-2022-322644.
PMID: 37852742DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Alon Harris, PhD
Indiana University School of Medicine
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
June 15, 2010
First Posted
June 17, 2010
Study Start
January 1, 2008
Primary Completion
July 3, 2014
Study Completion
July 3, 2014
Last Updated
March 7, 2017
Record last verified: 2017-03